About Us

Contact Us

Add Favorite
Home About Us Product News Order Career Contact

                                                                                                            

           APIs&Intermediates Chemicals of Shanghai APIs Chemical Co., Ltd 

           

             

 

Product Indentification
 

 

Name:   CEP-18770
Synonyms:   CEP-18770; Boronic acid, B-[(1R)-1-[[(2S,3R)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]-;

[(1R)-1-[[(2S,3R)-3-Hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid

CAS Registry Number:   847499-27-8
Molecular Formula:   C21H28BN3O5
Molecular Weight:    413.27
Molecular Structure:    

 

 

              

                  

                   Purity:98%min

 

 

                   Storage: 4 deg C

   

  

                   Inquiry

 

 

Related Proteasome inhibitors

 

        Bortezomib|179324-69-7

 

        Carfilzomib|868540-17-4

 

         Ritonavir|155213-67-5

 

        565454-88-8|ER805751

 

        133407-82-6|MG132

 

        198904-31-3|Atazanavir

 

           CEP-18770|847499-27-8

 

        437742-34-2|Marizomib

 

 

      

Related pages:


     Search CEP-18770  in google
     Search CAS 847499-27-8  in google
     Search C21H28BN3O5  in google

 

 

 

Information:

 

CEP-18770 is An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Proteasome inhibitor CEP 18770 represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. In vitro studies indicate that this agent exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells relative to the proteasome inhibitor bortezomib. The intracellular protein IkappaBalpha functions as a primary inhibitor of the proinflammatory transcription factor NF-kappaB. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

 

 

 

Home About Us Product News Order Career Contact
 Copyright @ 2010-2011 APIs All rights reserved
 

 

 

No_Right_Click

 

No_Right_Click